Regeneron Collaborates with Alnylam to Discover, Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

 Regeneron Collaborates with Alnylam to Discover, Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

Regeneron Collaborates with Alnylam to Discover, Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

Shots:

  • Alnylam & Regeneron to co-discover RNAi therapies for eye and CNS diseases. Alnylam to receive $400M upfront, $400M equity at a price of $90/share, $200M as milestones and royalties on sales of products. Regeneron to get rights to develop & commercialize candidates for ocular diseases and to jointly lead CNS diseases program with an option to candidate selection with equal profit sharing
  • The companies also target genes expressed in the liver including the evaluation of Regeneron’s P-I pozelimab (REGN3918) and Alnylam’s P-II cemdisiran. Regeneron to lead the combination’s development while Alnylam to take care of monothx with no changes in 2018 deal for NASH
  • The companies collaborate for 5yrs involving 30 targets with an option to extend. Alnylam to receive $2.5M at the initiation of each program and $2.5M at the identification of lead candidates with $30M as annual discovery funding for each target

Click here to read full press release/ article | Ref: Alnylam | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post